Medtronic (MDT) is expected to report Q4 earnings on Tuesday, May 25 before the market open with a conference call scheduled for 8 am ET.
Guidance:
Analysts are looking for EPS of 88c on revenue of $4.19B. The consensus range is 86c-91c for EPS, and $4.11B-$4.27B for revenue. The company raised the lower end of its FY10 EPS guidance to $3.20-$3.22 in late February.
Positive catalysts for Medtronic this quarter include the product recalls that its competitor Boston Scientific (BSX) is currently experiencing, expanding global sales in the ICD market, domestic and international demand for the Endeavor stent, and sales of its new heart valve products. Negative catalysts for the quarter may be seen coming from a maturing domestic ICD market with slowing sales growth.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment